Hideki Nakajima

Hideki Nakajima

Auto-generated profile, based on publicly available information

Hideki Nakajima

Department of Dermatology, Kochi Medical School Kochi University Kochi Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Journal of Dermatological Science
Verified
Journal Article
Closed access
HNHideki Nakajima
Hideki Nakajima
SSSatoshi Serada
Satoshi Serada
MFMinoru Fujimoto
Minoru Fujimoto
TNTetsuji Naka
Tetsuji Naka
SSShigetoshi Sano
Shigetoshi Sano

22 October 2012 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
HNH. Nakajima
H. Nakajima
KNK. Nakajima
K. Nakajima
MTM. Tarutani
M. Tarutani
SSS. Sano
S. Sano

20 May 2013 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
IMImajoh Masayuki
Imajoh Masayuki
YHYumiko Hashida
Yumiko Hashida
HNHideki Nakajima
Hideki Nakajima
SSShigetoshi Sano
Shigetoshi Sano
MDMasanori Daibata
Masanori Daibata

9 December 2014 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
TKTakashi Karashima
Takashi Karashima
YTYoshinori Taniguchi
Yoshinori Taniguchi
TSTsutomu Shimamoto
Tsutomu Shimamoto
TNTomoya Nao
Tomoya Nao
HNHiroshi Nishikawa
Hiroshi Nishikawa
TSTaro Shuin
Taro Shuin
We report a case of a 33-year-old man who presented with immunoglobulin (Ig)G4-related disease (IgG4-RD) forming a pseudotumor in the left paratesticular region during oral administration of corticosteroid for Wells syndrome, which involves cellulitis with eosinophilia. The patient was introduced to our institution from a private hospital with a 3-month history of asymptomatic left scrotal mass. A 5-cm diameter nodule was palpable in the left scrotum. Tumor lesion in the left paratestis involving the epididymis and spermatic cord was observed on computed tomography and magnetic resonance imaging. Blood testing showed no abnormalities other than a minimal increase in C-reactive protein levels. Urine examination likewise revealed no significant findings. Left radical orchidectomy was performed under a diagnosis of left paratesticular neoplasm suspected as malignant tumor. The tumor was pathologically identified as IgG4-RD of the left paratestis involving the epididymis and spermatic cord. We present a first description of IgG4-RD in a patient with Wells syndrome and the ninth case of IgG4-RD in a scrotal organ, and discuss this very rare entity with reference to the literature. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/13000_2014_225

18 October 2021 in The Journal of Dermatology
Verified
Journal Article
Open access
PDF file
THToshihisa Hamada
Toshihisa Hamada
AMAkimichi Morita
Akimichi Morita
HSHiraku Suga
Hiraku Suga
HBHikari Boki
Hikari Boki
TFTaku Fujimura
Taku Fujimura
MSMakoto Sugaya
Makoto Sugaya
To establish real‐world evidence about the safety and efficacy of bexarotene for Japanese patients with cutaneous T‐cell lymphoma, we conducted a nationwide cohort study using data from post‐marketing surveillance for bexarotene treatment. In total, 294 patients with cutaneous T‐cell lymphoma were identified between June 2016 and June 2018. Of these, 267 patients were included as the safety analysis set. Of the 267 patients, 175 were included in the efficacy analysis set. Of these, 139 patients had mycosis fungoides, including 46 with early stage disease and 93 with advanced stage disease. Among the 139 patients with mycosis fungoides, the objective response rate was 46.8%. A significant difference in objective response rate was detected between patients who started with bexarotene at 300 mg/m2 (61.6%) and patients who started with bexarotene at less than 300 mg/m2 (22.6%, p < 0.001). Of the 139 patients with mycosis fungoides, 92 were treated with a combination of bexarotene plus photo(chemo)therapy. A significant difference in objective response rate was seen between bexarotene with a combination of photo(chemo)therapy (57.6%) and bexarotene without a combination of photo(chemo)therapy (25.5%, p < 0.001). Starting bexarotene at 300 mg/m2 and combination with photo(chemo)therapy were detected as independent factors influencing response. Common treatment‐related adverse events included hypothyroidism (85.8%), hypertriglyceridemia (68.5%), hypercholesterolemia (43.8%), and neutropenia (21.3%). Hypertriglyceridemia, hypercholesterolemia, and neutropenia occurred more frequently in patients who started with bexarotene at 300 mg/m2 than patients who started with bexarotene at less than 300 mg/m2 (hypertriglyceridemia, 76.4% vs. 57.0%, p = 0.001; hypercholesterolemia, 49.0% vs. 36.4%, p = 0.045; neutropenia, 28.0% vs. 12.1%, p = 0.002; respectively). The present study indicates that starting bexarotene at 300 mg/m2 and combination of photo(chemo)therapy offer a promising efficacy for the treatment of patients with mycosis fungoides. Efficacy of low‐dose bexarotene plus photo(chemo)therapy should be evaluated in future.

20 January 2017 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
TKTomoko Kudo
Tomoko Kudo
AFAi Fujioka
Ai Fujioka
MKMasataka Korenaga
Masataka Korenaga
HYHiroshi Yamasaki
Hiroshi Yamasaki
YMYasuyuki Morishima
Yasuyuki Morishima
SSShigetoshi Sano
Shigetoshi Sano